Comparison of Cannabis-Based Medicinal Product Formulations for Fibromyalgia: A Cohort Study.

IF 0.9 Q3 ANESTHESIOLOGY
Surya Sridharan, Simon Erridge, Carl Holvey, Ross Coomber, Wendy Holden, James J Rucker, Michael Platt, Mikael H Sodergren
{"title":"Comparison of Cannabis-Based Medicinal Product Formulations for Fibromyalgia: A Cohort Study.","authors":"Surya Sridharan, Simon Erridge, Carl Holvey, Ross Coomber, Wendy Holden, James J Rucker, Michael Platt, Mikael H Sodergren","doi":"10.1080/15360288.2024.2414073","DOIUrl":null,"url":null,"abstract":"<p><p>This cohort study aims to assess the outcomes of fibromyalgia patients enrolled in the UK Medical Cannabis Registry prescribed a homogenous selection of cannabis-based medicinal products (CBMPs). A cohort study of fibromyalgia patients treated with oils (Adven<sup>®</sup>, Curaleaf International, UK), dried flower (Adven<sup>®</sup>, Curaleaf International, UK) or both CBMPs was performed. Primary outcomes were changes from baseline at 1, 3, 6 and 12 months in validated patient-reported outcome measures. Secondary outcomes included descriptive analysis of adverse events. One hundred and forty-eight participants were treated with oils (<i>n</i> = 77; 52.03%), dried flower (<i>n</i> = 14; 9.46%) or both (<i>n</i> = 57; 38.51%). Improvements in the generalized anxiety disorder-7 questionnaire, single-item sleep quality scale, fibromyalgia symptom severity score and EQ-5D-5L Index values were observed at each follow up period compared to baseline (<i>p</i> < 0.050). Thirty-six (24.32%) patients experienced 648 adverse events. Improvements were observed across all primary outcomes with no differences observed across different formulations of CBMPs. Adverse events were reported by one-quarter of participants and were more likely to reported by cannabis naïve patients. This present work through focusing on a homogeneous group of CBMPs can help inform randomized controlled trials after observing signals of improvement associated with a specific cultivar of CBMPs.</p>","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pain & Palliative Care Pharmacotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/15360288.2024.2414073","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

This cohort study aims to assess the outcomes of fibromyalgia patients enrolled in the UK Medical Cannabis Registry prescribed a homogenous selection of cannabis-based medicinal products (CBMPs). A cohort study of fibromyalgia patients treated with oils (Adven®, Curaleaf International, UK), dried flower (Adven®, Curaleaf International, UK) or both CBMPs was performed. Primary outcomes were changes from baseline at 1, 3, 6 and 12 months in validated patient-reported outcome measures. Secondary outcomes included descriptive analysis of adverse events. One hundred and forty-eight participants were treated with oils (n = 77; 52.03%), dried flower (n = 14; 9.46%) or both (n = 57; 38.51%). Improvements in the generalized anxiety disorder-7 questionnaire, single-item sleep quality scale, fibromyalgia symptom severity score and EQ-5D-5L Index values were observed at each follow up period compared to baseline (p < 0.050). Thirty-six (24.32%) patients experienced 648 adverse events. Improvements were observed across all primary outcomes with no differences observed across different formulations of CBMPs. Adverse events were reported by one-quarter of participants and were more likely to reported by cannabis naïve patients. This present work through focusing on a homogeneous group of CBMPs can help inform randomized controlled trials after observing signals of improvement associated with a specific cultivar of CBMPs.

比较治疗纤维肌痛的大麻药用产品配方:队列研究。
这项队列研究旨在评估英国医用大麻登记处登记的纤维肌痛患者使用同类大麻药用产品 (CBMP) 的疗效。对接受精油(Adven®,英国 Curaleaf International 公司)、干花(Adven®,英国 Curaleaf International 公司)或两种 CBMP 治疗的纤维肌痛患者进行了一项队列研究。主要结果是在 1、3、6 和 12 个月时,经验证的患者报告结果指标与基线相比的变化。次要结果包括不良事件的描述性分析。148 名参与者接受了精油治疗(人数=77;52.03%)、干花治疗(人数=14;9.46%)或两种治疗(人数=57;38.51%)。与基线相比,每个随访期的广泛性焦虑症-7 问卷、单项睡眠质量量表、纤维肌痛症状严重程度评分和 EQ-5D-5L 指数值均有所改善(P<0.05)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.60
自引率
9.10%
发文量
40
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信